Local Regulatory Experts
Connect with regulatory affairs consultancies specializing in this region.
Qualtech Consulting Corporation
Taiwan, China, Japan, Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Australia, Germany, Korea, Thailand, USA
A specialized medical device consulting firm offering a one-stop solution for complex global regulatory challenges. We offer real-time regulatory and clinical support, local representation, and QMS services across 13 markets, ensuring efficient market entry and compliance.
Cobridge Co., Ltd.
Tokyo, Japan
We assist medical device companies with the medical device registration and approval in Japan. Regulatory consulting services and DMAH services for foreign manufacturers to enter Japanese market.
MDREX, Medical Device, Digital Health Consulting Group
Seoul, Republic of Korea (HQ), Japan Office
We offer total solutions for market entry in South Korea and global expansion (e.g., Japan, USA, Europe). Key areas include product approval, reimbursement listings (HIRA), and Quality System certification (KGMP). They are particularly strong in innovative products like SaMD, medical wearables, and 3D printing for medical use, and provide in-depth expertise in cybersecurity and clinical trial planning.
CMIC Holdings Co., Ltd.
Tokyo, Japan (HQ), Osaka, Japan, Beijing, China, Seoul, South Korea, Taipei, Taiwan, Singapore, New York, USA, London, UK, Frankfurt, Germany, Sydney, Australia
We operate globally, specializing in accelerating the development, manufacturing, and commercialization of drugs and medical devices. Their expertise spans Phase I to IV clinical trials, regulatory affairs, quality assurance, and manufacturing, with a strong focus on the Japanese and Asian markets. Key services include clinical operations (CRO), manufacturing (CDMO/CMO), site management (SMO), and comprehensive health analysis and solutions.
March 25, 2025
Approximately 5 minutes
Standards for Marketing Approval of Oral Remedies for Rhinitis in Japan
Standards for Marketing Approval of Oral Remedies for Rhinitis (Japan)
The Standards for Marketing Approval of Oral Remedies for Rhinitis were issued by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan under Notification PB No.23 on March 25, 2015, with partial revision on December 14, 2015. These standards define criteria for approval of oral medicines intended to relieve rhinitis symptoms, excluding cold remedies, anti‑allergic agents and Kampo‑based remedies. Remedies that do not conform to these standards require submission of efficacy and safety data and justification for combinations. (PMDA, 000272491.pdf).
Scope
The standards apply to oral medicines formulated to relieve symptoms of rhinitis; cold remedies, anti‑allergic agents and Kampo‑based formulas are excluded. (PMDA, 000272491.pdf).
Active Ingredients
Table 1 in the standards lists active ingredients permitted for use and categorizes them into Columns I to V, with specific rules on combinations: only one ingredient from certain columns may be used in combination, and some combinations are prohibited (e.g., dl‑methylephedrine hydrochloride with l‑methylephedrine hydrochloride). (PMDA, 000272491.pdf).
Quantities of Active Ingredients
The maximum daily dose for each active ingredient is specified in Table 1. The maximum single dose is one‑third of the maximum daily amount, except oral solutions and syrups where it is one‑sixth. When combining certain ingredients, the sum of dose fractions must not exceed specified limits. Lower limits for daily doses also apply based on ingredient column. (PMDA, 000272491.pdf).
Dosage Forms
Approved dosage forms include capsules, granules, pills, powders, tablets, oral solutions (excluding elixirs) and syrups. (PMDA, 000272491.pdf).
Dosage and Administration
The general regimen is oral dosing three times a day, with intervals of at least four hours. For oral solutions and syrups, dosing up to six times per day is acceptable if taken at approximately four‑hour intervals. Dosage for infants under 3 months is not approved. Age‑ and formulation‑based restrictions apply for children, with maximum daily doses adjusted by age coefficients. The maximum single dose for oral solutions and syrups is 10 mL. (PMDA, 000272491.pdf).
Indications
Indications must fall within relief of symptoms due to acute rhinitis, allergic rhinitis or sinusitis, including sneezing, runny nose (excessive nasal discharge), stuffy nose, watery eyes, sore throat and dull headache. (PMDA, 000272491.pdf).
Packaging Units
The maximum volume for containers of oral solutions and syrups is limited to a four‑day supply at the maximum daily dose. (PMDA, 000272491.pdf).
Summary
These standards form the regulatory framework for marketing approval of oral rhinitis remedies in Japan. Compliance with active ingredient lists, dosage limits, dosage forms, administration regimens, indications and packaging rules is essential to obtain approval. (PMDA, 000272491.pdf).
Have a Question?
Ask our experts about this topic. We'll do our best to respond to your question.
Related Articles
Approximately 5 minutes
Japan: Standards for Marketing Approval of OTC Cold Remedies (MHLW Notification PB No.28)
A practical overview of Japan’s OTC cold remedy approval standards: permitted dosage forms, dosing/age limits, allowable indications, and key constraints that shape formulation and labeling.
Approximately 5 minutes
Standards for Marketing Approval of Cold Remedies in Japan
Regulatory standards for OTC cold remedies in Japan
Approximately 5 minutes
Standards for Marketing Approval of Antitussives and Expectorants in Japan
Regulatory criteria for OTC antitussives and expectorants in Japan
Approximately 5 minutes
Standards for Marketing Approval of Gastrointestinal Medicines in Japan
Regulatory criteria for OTC gastrointestinal medicines in Japan
Approximately 5 minutes
Standards for Marketing Approval of Laxatives in Japan
Regulatory criteria for OTC laxatives in Japan
Approximately 5 minutes
Standards for Marketing Approval of Antivertigo Medicines in Japan
Regulatory criteria for antivertigo medicines in Japan